Delaware biopharma company secures $95 million in funding

AdvertisementPrelude Therapeutics,  a privately held, clinical-stage biopharmaceutical company secured $60 million in Series B financing. Investments to date total  $95 million. The company is headed by a founder of Wilmington-based Incyte Corp. Prelude is located in the Delaware Innovation Space, a biotech incubator at the DuPont Experimental Station near Wilmington.  Since its launch in July 2016, … Continue reading Delaware biopharma company secures $95 million in funding